By Padmanabhan Ananthan March 9 (Reuters) - U.S. drugmaker Pfizer said on Monday its experimental drug for a chronic skin ...

FRANKFURT, March 9 (Reuters) - Roche's shares dropped more than 5% on Monday as the Swiss drugmaker failed to show that its ...

Diabetes and obesity drugs also lead to large reductions in adverse cardiovascular events, and the benefits aren’t just down ...

A key ratio for dividend investors when looking at dividend stocks is the payout ratio. Since it tells you how large the dividend is with respect to earnings, it can be a good gauge of whether or not ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) ...

Pfizer received its first obesity drug approval in China for Severwin, opening a new market for the company. The company also ...

Pfizer said its Phase 2 study of tilrekimig (PF-07275315), a trispecific antibody for atopic dermatitis, showed positive ...

AI is a valuable tool that could unlock significant value for these healthcare leaders and their shareholders.

Pfizer said a Phase 2 study of tilrekimig met its key goals in adults with moderate to severe atopic dermatitis, the most common form of eczema, and that it plans to accelerate the drug candidate into ...

Pfizer is ramping up plans for tilrekimig after a phase 2 win raised hopes that the once-monthly trispecific antibody could hold its own against approved eczema drugs. | Pfizer is ramping up plans for ...

Roche said the late-stage trial did not provide reliable evidence that ​the drug's use in combination with Pfizer's Ibrance ...

Investing.com -- Pfizer Inc (NYSE:PFE) shares fell 1.15% to $26.74 in premarket trading on Monday, despite the company reporting positive results from a mid-stage clinical trial of its experimental ...